HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by YAZIGI, R. Articles by ARRAZTOA, J. Search for Related Content PubMed PubMed Citation Articles by YAZIGI, R. Articles by ARRAZTOA, J.

Ifosfamide Treatment of Advanced Ovarian Cancer

From the Departments of Obstetrics and Gynecology and of Oncology, School of Medicine, Universidad Catolica de Chile; the Department of Obstetrics and Gynecology, Hospital Sotero del Rio; and the Department of Oncology, Hospital Militar, Santiago, Chile

Abstract

To determine the efficacy of ifosfamide in the treatment of advanced ovarian malignancy, 20 patients with stages III and IV epithelial ovarian cancer were treated with this agent. Of these, 15 received the drug as primary chemotherapy. The response rate was 33%, with a median duration remission of 13 months. Five patients were treated with ifosfamide after failure with previous chemotherapy; no responses were seen in this group. Hematuria was observed in 2% of the treatment cycles with the use of the antidote mercapto-ethan-sulfonate acid. This study shows that though ifosfamide is an active drug in the treatment of patients with advanced ovarian cancer, it is not superior traditional single alkylating agents.